Home

Scott L Burrows

CIK 1853327 · Chief Financial Officer · last filed 2026-09-03

Scott L Burrows is a Chief Financial Officer who has filed 29 SEC Form 4 insider transactions across 3 companies since 2021. The most recent filing, for SYRE, was dated Sep 3, 2026. Across all open-market trades the lifetime net is −$8.0M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $10.5M across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$10.49M

Companies

3

Total Filings

29

Lifetime Open-Market Net

-$7.98M

Filer Profile

Reported Address
C/O SPYRE THERAPEUTICS, INC.
221 CRESCENT STREET, SUITE 105
WALTHAM, MA 02453
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
SYRE Chief Financial Officer 100,210 $90.60 $9.08M -$7.68M 14 2026-09-03
Spyre Therapeutics, Inc. (AGLE) Delisted Chief Financial Officer — $12.01 — $0 1 2023-09-05
ARQT Chief Financial Officer 59,115 $23.89 $1.41M -$298.6K 9 2023-03-08

Recent Filings

29 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-09-03 SYRE Mixed −18,232 -$2.18M EDGAR
2026-08-05 SYRE Mixed — -$608.0K EDGAR
2026-08-03 SYRE Notice (144) −30,000 -$2.95M EDGAR
2026-07-02 SYRE Mixed — -$549.3K EDGAR
2026-06-26 SYRE Mixed — -$1.09M EDGAR
2026-06-25 SYRE Notice (144) −15,000 -$1.31M EDGAR
2026-06-03 SYRE Mixed — -$424.2K EDGAR
2026-05-01 SYRE Notice (144) −27,500 -$2.05M EDGAR
2026-05-01 SYRE Mixed — -$710.9K EDGAR
2026-04-03 SYRE Mixed — -$261.3K EDGAR
Showing 1–10 of 29
Page 1 of 3
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.